Special Issue

Recent Advances in the Development of Hybrid Drugs

Message from the Guest Editors

Hybrid drug development is a research field that is currently expanding. For a wide community of researchers around the world, the combination of two or more pharmacophores and/or drug-directing moieties in the same molecule is an attractive strategy for the design of new compounds with optimized pharmacodynamic profiles, and has already delivered promising results in the contexts of multidrug-resistant cancers, emerging antimicrobial-resistant bacteria, and others. Because of its undeniable potential, more and more researchers are integrating molecular hybridization into their strategic drug development approaches. Hence, this Special Issue of Pharmaceutics welcomes original research articles, communications and review articles dedicated to major advancements. breakthroughs and challenges in the design, synthesis and biological evaluation of organic, inorganic and organometallic hybrid drugs. Medicinal chemists working across all therapeutic areas are encouraged to contribute with research or literature overviews on this topic.

Guest Editors

Dr. Tânia S. Morais

Centro de Química Estrutural, Institute of Molecular Sciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal

Dr. Ana M. de Matos

Centro de Química Estrutural, Institute of Molecular Sciences, Faculdade de Ciências da Universidade de Lisboa, 1749-016 Lisboa, Portugal

Deadline for manuscript submissions

closed (20 April 2024)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/127100

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

